Sudo Biosciences Begins Dosing in Phase 1 Trial of TYK2 Inhibitor SUDO-550

CARMEL, Ind.--(BUSINESS WIRE)-- Sudo Biosciences, a biopharmaceutical company dedicated to creating leading-edge precision TYK2 (tyrosine kinase 2) inhibitors, has initiated dosing the first participants in a Phase 1 clinical trial of SUDO-550. This innovative brain-penetrant allosteric TYK2 inhibitor is being developed to treat neuroinflammatory diseases.

The Phase 1 clinical trial aims to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of SUDO-550 in healthy individuals. An essential part of the study is to confirm that the compound successfully crosses the blood-brain barrier.

“Entering the clinic is a crucial milestone in advancing SUDO-550 and positioning it as a leading brain-penetrant TYK2 inhibitor. This therapy has the potential to significantly improve the treatment of conditions like multiple sclerosis, ALS, and Alzheimer’s,” stated Ian Mills, Chief Medical Officer of Sudo Biosciences. “This is our second allosteric TYK2 inhibitor to reach clinical trials this year, following SUDO-286, which is currently undergoing two Phase 1 trials as a topical psoriasis treatment.”

Sudo Biosciences is focused on developing a range of highly potent and selective small molecule TYK2 pseudokinase inhibitors. These inhibitors aim to provide targeted therapies for a variety of autoimmune and neurological disorders.

SUDO-550 is an orally administered allosteric TYK2 inhibitor known for its high selectivity and potency, which helps minimize off-target effects. Preclinical studies have shown that SUDO-550 has excellent blood-brain barrier penetration, indicating its therapeutic potential for central nervous system diseases marked by compartmentalized neuroinflammation. These findings support the possibility of SUDO-550 becoming a top-tier treatment for multiple neuroinflammatory conditions.

SUDO-286, another product from the company, is a highly potent and selective topical TYK2 inhibitor, potentially the first and best in its class for treating psoriasis and other immune-mediated dermatologic diseases. The program entered clinical trials earlier this year and is under evaluation in two Phase 1 studies involving healthy volunteers and patients.

Sudo Biosciences is a biopharmaceutical company focused on creating innovative medicines to transform patients’ lives. The company’s development programs target the TYK2 pseudokinase domain, a crucial mediator in cytokine signaling pathways associated with various immune-mediated inflammatory diseases. The company’s pipeline includes next-generation TYK2 inhibitors such as a potential first and best-in-class brain-penetrant candidate for treating multiple sclerosis and other neurodegenerative diseases involving neuroinflammation, as well as a potential first and best-in-class topical candidate for immune-mediated skin conditions. Sudo Biosciences operates from Carmel, Indiana, with a presence across the United States and the United Kingdom.